Regeneron (REGN) jumps on robust Q4 earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Regeneron beats fourth-quarter revenue estimates
February 2, 2024 6:49 AM EST(Reuters) -Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target.
Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company's previously laid out targets in January.
... MoreRegeneron (REGN) Tops Q4 EPS by 109c
February 2, 2024 6:34 AM ESTRegeneron (NASDAQ: REGN) reported Q4 EPS of $11.86, $1.09 better than the analyst estimate of $10.77. Revenue for the quarter came in at $3.43 billion versus the consensus estimate of $3.3 billion.
For earnings history and earnings-related data on Regeneron (REGN) click here.
... More